Profound MedicalPROF +1.43%73 Equity-to-Asset is 0.81 as of Mar. 2026, which is 3% above its 10-year median of 0.79. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 855 Medical Devices & Instruments companies, Profound Medical ranks better than 77.43% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Profound Medical's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $59.42 Mil. Profound Medical's Total Assets for the quarter that ended in Mar. 2026 was $73.46 Mil.
Therefore, Profound Medical's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.81.
The historical rank and industry rank for Profound Medical's Equity-to-Asset or its related term are showing as below:
PROF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24 Med: 0.79 Max: 0.95
Current: 0.81
During the past 12 years, the highest Equity to Asset Ratio of Profound Medical was 0.95. The lowest was 0.24. And the median was 0.79.
PROF's Equity-to-Asset is ranked better than 77.43% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs PROF: 0.81
Profound Medical (NAS:PROF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Profound Medical Equity-to-Asset Related Terms
Profound Medical Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Profound Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Profound Medical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Profound Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a Equity-to-Asset of 0.81 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Profound Medical and its competitors. This is near median its historical median of 0.79. Over the past decade, Profound Medical's Equity-to-Asset has ranged from 0.24 to 0.95. According to the industry distribution chart, Profound Medical ranks #193 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 22.6%.
Is Profound Medical's Equity-to-Asset too high?
Profound Medical's current Equity-to-Asset of 0.81 is near median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 0.95. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Profound Medical's value of 0.81 is 24.6% above this industry median. Based on the distribution chart, Profound Medical ranks #193 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #193 out of 855 companies for Equity-to-Asset. This places Profound Medical in the top 23% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.65. Profound Medical's value of 0.81 is 24.6% above this benchmark. Historically, Profound Medical's own Equity-to-Asset has ranged from 0.24 to 0.95 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.65, Profound Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Equity-to-Asset of 0.81 is 24.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Equity-to-Asset is 0.81, which is near median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.45 — trading 47.8% below its estimated fair value. The current Equity-to-Asset is 0.81, which is near median its 10-year median of 0.79 and 24.6% above the Medical Devices & Instruments industry median of 0.65. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Profound Medical (PROF), the current Equity-to-Asset is 0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.45 is trading 47.8% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Equity-to-Asset: 0.81 (near median its 10-year median of 0.79)
GF Value™: $14.28 vs. price of $7.45 (47.8% below fair value)
Industry Position: 24.6% above the Medical Devices & Instruments median (#193 of 855)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
